PL408371A1 - Gel form the heparin sodium salt for skin application and method for producing it - Google Patents

Gel form the heparin sodium salt for skin application and method for producing it

Info

Publication number
PL408371A1
PL408371A1 PL408371A PL40837114A PL408371A1 PL 408371 A1 PL408371 A1 PL 408371A1 PL 408371 A PL408371 A PL 408371A PL 40837114 A PL40837114 A PL 40837114A PL 408371 A1 PL408371 A1 PL 408371A1
Authority
PL
Poland
Prior art keywords
producing
heparin
sodium salt
heparin sodium
gel form
Prior art date
Application number
PL408371A
Other languages
Polish (pl)
Other versions
PL229532B1 (en
Inventor
Krzysztof Bilmin
Paweł Grieb
Piotr Szopiński
Marek Lagner
Magdalena Przybyło
Original Assignee
Lipolek Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipolek Spółka Z Ograniczoną Odpowiedzialnością filed Critical Lipolek Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL408371A priority Critical patent/PL229532B1/en
Priority to PCT/IB2015/053974 priority patent/WO2015181746A1/en
Publication of PL408371A1 publication Critical patent/PL408371A1/en
Publication of PL229532B1 publication Critical patent/PL229532B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Rozwiązanie dotyczy lipidowej nanostrukturalnej postaci soli sodowej heparyny do zastosowań naskórnych, o lepkości nie mniejszej niż 7000 cP, charakteryzującej się tym, że w jej skład wchodzą: heparyna, bądź jej farmaceutycznie dopuszczalna sól, liposomy i/lub hydrożel, enzymy proteolityczne pochodzenia roślinnego lub ich stabilizowana pochodna, korzystnie chitosan, polijony dodatnie, rozpuszczalniki organiczne, bufor i substancje żelujące oraz opcjonalnie: konserwanty, przeciwutleniacze. Ujawniono również sposób wytwarzania lipidowej nanostrukturalnej postaci soli sodowej heparyny do zastosowań naskórnych.The solution applies to the lipid nanostructural form of heparin sodium for skin applications, with a viscosity of not less than 7000 cP, characterized in that it consists of: heparin or its pharmaceutically acceptable salt, liposomes and / or hydrogel, proteolytic enzymes of plant origin or their stabilized derivative, preferably chitosan, positive poly, organic solvents, buffer and gelling agents, and optionally preservatives, antioxidants. Also disclosed is a method for producing the lipid nanostructured form of sodium heparin for skin applications.

PL408371A 2014-05-29 2014-05-29 Gel form the heparin sodium salt for skin application and method for producing it PL229532B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL408371A PL229532B1 (en) 2014-05-29 2014-05-29 Gel form the heparin sodium salt for skin application and method for producing it
PCT/IB2015/053974 WO2015181746A1 (en) 2014-05-29 2015-05-27 Gel form of a heparin sodium salt for dermal administration, and a method for its preparation.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL408371A PL229532B1 (en) 2014-05-29 2014-05-29 Gel form the heparin sodium salt for skin application and method for producing it

Publications (2)

Publication Number Publication Date
PL408371A1 true PL408371A1 (en) 2015-12-07
PL229532B1 PL229532B1 (en) 2018-07-31

Family

ID=53404818

Family Applications (1)

Application Number Title Priority Date Filing Date
PL408371A PL229532B1 (en) 2014-05-29 2014-05-29 Gel form the heparin sodium salt for skin application and method for producing it

Country Status (2)

Country Link
PL (1) PL229532B1 (en)
WO (1) WO2015181746A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110204632A (en) * 2019-04-04 2019-09-06 姜德亮 A kind of intestinal mucosa extraction heparin sodium crude salt solution technique
CN114557928B (en) * 2022-03-01 2023-09-29 上海联衡生物科技有限公司 Skin care product for whitening and removing yellow and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100793825B1 (en) 2006-07-27 2008-01-11 (주)아모레퍼시픽 Cosmetic composition for exfoliating skin keratin
IT1400232B1 (en) * 2010-05-07 2013-05-24 Advance Holdings Ltd PHARMACEUTICAL COMPOSITION TOPICAL COMPARING EPARIN
DK2734213T3 (en) * 2011-07-19 2018-08-13 Baxalta GmbH RESORPTION PROMOTERS ADDITIVES TO IMPROVE ORAL FORMULATION OF NON-ANTI-COATING SULPHATE POLYSACCHARIDS

Also Published As

Publication number Publication date
PL229532B1 (en) 2018-07-31
WO2015181746A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
MX2018010788A (en) Ophthalmological composition.
IL288159B (en) Devices, methods, and compositions useful in cryo-preservation, -storage, -transport, and application of therapeutic mammalian cells
CR20150476A (en) OXOPYRIDINE SUBSTITUTED DERIVATIVES AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
NZ713029A (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
EP2996172A3 (en) Biocompatibility of biomedical energization elements
IN2014DN09937A (en)
WO2014184677A3 (en) Eye care devices and methods
ES2531066T3 (en) An intra-articular supplement for use in the treatment of diseases and joint injuries
MX2016014050A (en) Combination of a hyaluronic acid and of a sulphated polysaccharide.
EP4233926A3 (en) Methods of manufacturing injectable gels comprising cross-linked hyaluronic acid and hydroxyapatite
MY193650A (en) Extracellular matrix compositions
EA201592073A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COLLAGEN AND SODIUM HYALURONATE
MD3482754T2 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
ES2663806T8 (en) Heterocyclic nitrogen derivatives and their application in the treatment of tissue fibrosis
EA201992832A1 (en) SCREAM INTRODUCTION ADAMTS13
RS54733B1 (en) Tritoqualine for use in the treatment of cystic fibrosis
CO2017001626A2 (en) Anti-orai1 antibody
CY1124538T1 (en) USING PRG4 TO IMPROVE DYNAMIC VISUAL ACUITY AND HIGHER-ORDER ABIRATIONS
CL2012001835A1 (en) Use of a formulation comprising a viscogenic agent and moxifloxacin to prepare a medicament useful for treating the middle ear.
CL2020000221A1 (en) Compositions comprising amino acids for use in the treatment of diseases related to mitochondrial dysfunction.
PL408371A1 (en) Gel form the heparin sodium salt for skin application and method for producing it
WO2015108605A3 (en) Microbial production of branched medium chain alcohols, such as 4- methylpentanol
WO2014158685A3 (en) Tetracera asiatica extracts and methods of use
RS54013B1 (en) Viscoelastic gels in ophthalmic surgery